De Gasperi Andrea, Feltracco Paolo, Ceravola Elias, Mazza Ernestina
a2° Service Anesthesia CCM, Ospedale Niguarda Ca Granda, Milan bDepartment of Medicine, Anesthesia and Intensive Care Unit, Padova University Hospital, Padova, Italy.
Curr Opin Crit Care. 2014 Aug;20(4):411-9. doi: 10.1097/MCC.0000000000000120.
Major improvements in perioperative care and immunobiology have not abated the risk for severe pulmonary complications after solid-organ transplantation. The aim of this study is to update information on infectious and noninfectious pulmonary complications after solid-organ transplantation, addressing epidemiology, risk factors, diagnostic workup, and management.
Infectious and noninfectious postoperative pulmonary complications depend on the grafted organ and the anatomical site of transplantation. Kidney transplants have the lowest incidence of pulmonary complications, the highest being reported for heart, lung, and liver recipients. Respiratory tract infections, ranking first in heart and lung transplants and second in liver recipients, are a common cause of mortality. Risk factors include end-stage organ disease, comorbidities, perioperative procedures, and graft function. Factors specific for infections are timeline, state of immunosuppression, and graft dysfunction. Nosocomial multi-drug resistant pathogens are frequently responsible for the most severe infections. Aggressive diagnostic workup, early and broad empiric antiinfective therapy, and deescalation policy are the mainstays of their management. The role of intraoperative protective ventilation is under scrutiny.
Pulmonary complications after solid-organ transplantation, and particularly infections, are able to compromise the extremely good results of the transplant procedures. Solid-organ transplantation recipients challenge the ICU physician with unique aspects of their post-transplant course, adding, in an already critical patient, the immunosuppressed state and the quality of the functional recovery of the graft.
围手术期护理和免疫生物学虽有重大进展,但实体器官移植后严重肺部并发症的风险并未降低。本研究旨在更新实体器官移植后感染性和非感染性肺部并发症的相关信息,涉及流行病学、危险因素、诊断检查及管理。
感染性和非感染性术后肺部并发症取决于移植器官及移植的解剖部位。肾移植受者肺部并发症发生率最低,心脏、肺和肝移植受者的发生率最高。呼吸道感染在心脏和肺移植受者中位居首位,在肝移植受者中位居第二,是常见的死亡原因。危险因素包括终末期器官疾病、合并症、围手术期操作及移植功能。感染特有的因素包括时间线、免疫抑制状态及移植功能障碍。医院内多重耐药病原体常导致最严重的感染。积极的诊断检查、早期广泛的经验性抗感染治疗及降阶梯策略是其管理的主要手段。术中保护性通气的作用正在研究中。
实体器官移植后的肺部并发症,尤其是感染,会影响移植手术原本极为良好的效果。实体器官移植受者在移植后的病程中存在独特问题,给重症监护病房医生带来挑战,在本就病情危急的患者基础上,又增加了免疫抑制状态及移植功能恢复质量方面的问题。